Telectronics N.v.

Telectronics Pacing Systems, Inc.

Richard Grevis

Loraine K Holley

Philip J Maker

Geoffrey A Drane

Norma L Gilli

Paul Dyson

Lorain K Holley

Andrew Sands

Andrew Parle

Rodney Parkin

An arrhythmia control system and method having automatic determination of the tachycardia confirmation interval. The interval is dynamically set at the minimum of an absolute detection interval and a value calculated as a function of either average sinus interval or tachycardia cycle length or both. The continued presence or the reversion of a pathologic tachycardia can be reliably confirmed, particularly when the patient experiences an elevated heart rate due to, for example, exercise, prior to onset of the tachycardia.

Apparatus and method for detecting and treating cardiac tachyarrhythmias

An apparatus and method for tachyarrhythmia reversion uses multiple sensitivities programmed for automatic operation. A first (medium) sensitivity is used normally for the detection of sinus rhythm and ventricular tachycardia. A second (higher) sensitivity is designed for differentiating ventricular fibrillation from asystole. A third (lower) sensitivity can also be programmed into the device to differentiate between R-waves and high amplitude current of injury T-waves which may occur post shock. Following the delivery of antitachycardia therapy in the form of either antitachycardia pacing therapy or cardioversion shock therapy, there is a pause, or post therapy pacing delay for a period of time prior to the commencement of bradycardia support pacing. The magnitude of the delay period is substantially greater than the normal bradycardia support pacing standby interval.

Apparatus and method for controlling multiple sensitivities in

Apparatus and method for treating tachyarrhythmias wherein the presence of a patient tachyarrhythmia is detected and a first antitachyarrhythmia therapy (antitachycardia pacing) is given at a first energy level. The haemodynamic condition of the patient is measured and a length of time to therapy switchover is continually derived during the application of the first antitachyarrhythmia therapy. The length of time to switchover is a function of the haemodynamic condition of the patient. When the time following detection of the patient tachyarrhythmia exceeds the length of time to switchover, a second antitachyarrhythmia therapy (a high energy shock) at a second energy level is provided. The average cardiac cycle length may be used as an indicator of the haemodynamic condition.

Apparatus and method for therapy adjustment in implantable

Growing community of inventors

Rose Bay, Australia

Richard Grevis